|
A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS Clinical research trials and A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS. A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS clinical trial. Participants frequently get the best healthcare available for their A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS  A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS
A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS
For Condition: Sarcoma, Kaposi,HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: To study the safety and maximum tolerated dose (MTD) of combined chemotherapy when it is administered to patients with advanced Kaposi's sarcoma together with one of two different doses of zidovudine (AZT). The combination of AZT and chemotherapy may be effective in treating the tumor as well as preventing the life-threatening infections when used for patients with AIDS and Kaposi's sarcoma. The MTD of combined chemotherapy is being determined so that the information will be available for future studies, when the relative effectiveness of the two doses of AZT has been learned.
Details: The combination of AZT and chemotherapy may be effective in treating the tumor as well as preventing the life-threatening infections when used for patients with AIDS and Kaposi's sarcoma. The MTD of combined chemotherapy is being determined so that the information will be available for future studies, when the relative effectiveness of the two doses of AZT has been learned. AMENDED: AZT by mouth. If the treatment is well tolerated, subsequent groups of patients are started on increasing doses of doxorubicin combined with the same dose of bleomycin and vincristine. After determination of the MTD of chemotherapy in combination with AZT, the 2nd phase begins in which AZT is given and the first group of patients is given bleomycin and vincristine only. If this combination is well tolerated, then the subsequent groups are started on increasing doses of doxorubicin with the same dose of bleomycin, vincristine and AZT. The MTD of chemotherapy in combination with AZT is then determined. Patients achieving maximum response to the tumor are maintained on AZT alone. This is an outpatient study, and patients are seen every 2 weeks for evaluation, with a physical examination every month. Original design: The combination of chemotherapy and AZT is given to groups of four patients each, the first group beginning with bleomycin and vincristine, without the addition of doxorubicin. The chemotherapy is given intravenously every 2 weeks. This is combined first with AZT by mouth.
Eligibility:
Study Type: Interventional, Treatment, Dose Comparison
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Medication for grades 1 and 2 oral toxicity. Antiemetic agents, except steroids, for gastrointestinal toxicity. Toxicity grades according to NIAID Recommendations for Grading of Acute and Subacute Toxic Effects (Adults). Patients must demonstrate any of the following clinical and laboratory findings: - 25 or more mucocutaneous lesions with or without lymphedema. - Progressive Kaposi's sarcoma (KS) with 10 or more new lesions in the month prior to study entry or visceral involvement. - Oral mucosal lesion(s) requiring therapy. - Prior history of Pneumocystis carinii pneumonia (PCP) or Mycobacterium avium intracellulare. Patients with any of the following constitutional symptoms with no etiology established may be included: - Temperature > 38 degrees C and/or drenching night sweats for more than 1 month. - Watery diarrhea (= or > 3 stools/day) for 2 or more weeks. - Weight loss > 10 percent of normal. Patients with carcinoma in situ of the cervix or localized squamous or basal cell carcinoma of the skin may be included. Active alcohol or drug abuse sufficient to prevent adequate compliance with study therapy. Exclusion Criteria Co-existing Condition: Patients with the following conditions will be excluded: - Peripheral sensory or motor neuropathy. - Opportunistic infections requiring therapy. - Significant pulmonary (exertional dyspnea with minimal exercise) or cardiac insufficiency (New York Heart Association, status > 2). - Serious neuropsychiatric illness which would prevent informed consent of intensive treatment. Concurrent Medication: Excluded: - Any drugs causing anemia, neutropenia, or significant risk of nephrotoxicity. Patients with a history of other systemic malignancies or lymphomas, except carcinoma in situ of the cervix or localized squamous or basal cell carcinoma of the skin, will be excluded from the study. Prior Medication: Excluded: - Systemic antineoplastic chemotherapy. - Excluded within 30 days of study entry: - Any other investigational therapy. - Antiretroviral agents (zidovudine, ribavirin). - Immunomodulating agents (steroids, interferons, naltrexone, isoprinosine, and interleukin-2).
Total Enrollment: 36
Location and Contact Information:
Overall Study Official:
PSGill, Study Chair,
Los Angeles County - USC Med Ctr
Los Angeles, California, 90033
United States
UCLA CARE Ctr
Los Angeles, California, 90095
United States
USC School of Medicine / Norris Cancer Hosp
Los Angeles, California, 90033
United States
Additional Information:
Study ID Numbers: ACTG 075;
Study Start Date:
Record last reviewed: August 1992
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000987
Other Sarcoma, Kaposi Studies:
1. A Study of Targretin Capsules in Patients with AIDS-Related Kaposi's Sarcoma
2. SU5416 in Patients with AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment
3. A Study of Ro 24-7429 in Patients with HIV-Related Kaposi's Sarcoma
4. Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients with AIDS-Related Kaposi's Sarcoma
5. Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
Related Studies:
Other Sarcoma, Kaposi Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients with AIDS
|
|
|
|
|
|
|
|
